Patrys Ltd
Company Profile
Business description
Patrys Ltd is a biopharmaceutical company focused on developing novel antibody-based therapies prominently for cancer and related inflammatory diseases. Its core technology platform involves antibodies that penetrate cell nuclei and inhibit cancer cell DNA repair mechanisms. The company advances therapeutic candidates from its antibody platforms, including ones licensed from Yale University, with ongoing preclinical and clinical development activities. Patrys generates revenue through licensing agreements and collaborations linked to its antibody technologies. Its operations and development efforts span Australia and the United States.
Contact
385 Bourke Street
Suite 2, Level 11
MelbourneVIC3000
AUST: +61 396703273
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
23
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,277.90 | 18.60 | -0.20% |
| CAC 40 | 8,060.13 | 85.28 | 1.07% |
| DAX 40 | 24,597.13 | 211.35 | 0.87% |
| Dow JONES (US) | 46,601.78 | 1.20 | -0.00% |
| FTSE 100 | 9,548.87 | 65.29 | 0.69% |
| HKSE | 26,829.46 | 128.31 | -0.48% |
| NASDAQ | 23,043.38 | 255.02 | 1.12% |
| Nikkei 225 | 48,062.49 | 327.50 | 0.69% |
| NZX 50 Index | 13,582.81 | 14.33 | 0.11% |
| S&P 500 | 6,753.72 | 39.13 | 0.58% |
| S&P/ASX 200 | 8,973.70 | 21.30 | -0.24% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |